UroGen continues to climb after bladder cancer drug approval

3 weeks ago 2

• Healthcare
• On the Move

Maxiphoto

• After closing Thursday up ~52% following the U.S. FDA's approval of its bladder cancer drug Zusduri (mitomycin), UroGen Pharma (NASDAQ:URGN) is up ~10% in Friday morning trading.
• Zusduri is approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
• On Friday, Guggenheim doubled

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. UroGen continues to climb after bladder cancer drug approval